Akebia Therapeutics (AKBA) Common Equity (2016 - 2025)
Historic Common Equity for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $41.6 million.
- Akebia Therapeutics' Common Equity rose 18252.05% to $41.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 million, marking a year-over-year increase of 18252.05%. This contributed to the annual value of -$49.2 million for FY2024, which is 6081.94% down from last year.
- Akebia Therapeutics' Common Equity amounted to $41.6 million in Q3 2025, which was up 18252.05% from $29.2 million recorded in Q2 2025.
- Over the past 5 years, Akebia Therapeutics' Common Equity peaked at $213.9 million during Q1 2021, and registered a low of -$1.6 billion during Q3 2022.
- Its 5-year average for Common Equity is -$55.0 million, with a median of $5.2 million in 2022.
- In the last 5 years, Akebia Therapeutics' Common Equity crashed by 123084.58% in 2022 and then skyrocketed by 19017.9% in 2025.
- Akebia Therapeutics' Common Equity (Quarter) stood at $74.0 million in 2021, then plummeted by 92.93% to $5.2 million in 2022, then crashed by 684.78% to -$30.6 million in 2023, then tumbled by 60.82% to -$49.2 million in 2024, then soared by 184.56% to $41.6 million in 2025.
- Its Common Equity was $41.6 million in Q3 2025, compared to $29.2 million in Q2 2025 and $24.6 million in Q1 2025.